Daraxonrasib Moves Pancreatic Cancer Treatment Forward, but the First-Line Question Is Still Open
Pancreatic ductal adenocarcinoma has long been a disease of therapeutic exhaustion. _KRAS_ mutations drive more than 90% of tumors, yet for decades the pathway seemed inaccessible to drug development, and even the first KRAS inhibitors produced only limited activity in advanced disease. Daraxonrasib breaks that pattern by targeting the active RAS state, the biology most relevant to pancreatic cancer, and its phase III performance in the second-line setting has already changed expectations. The harder question now is not whether the drug works, but when it should be used.
In RASolute 302, 500 patients were enrolled over 13 months, with eligibility extending to people who had received one prior line of therapy in the metastatic setting or who progressed within 6 months of neoadjuvant or adjuvant treatment. The trial included patients regardless of RAS mutation status, although the coprimary endpoints focused on the RAS G12 population, which represented nearly 92% of the cohort. Daraxonrasib produced a median overall survival of 13.2 months versus 6.6 to 6.7 months with chemotherapy, with a hazard ratio of 0.40 in both the RAS G12 and overall analyses. Progression-free survival also improved in both populations.
The signal is large enough to draw attention, and it has.
Survival Gain, Toxicity, and the Limits of Early Data
The early readout is striking, but data maturity matters. Median follow-up stood at 8.5 months, a short interval in a disease where survival curves can continue to shift as censoring accumulates and subsequent therapies intervene. Early stopping can magnify the apparent size of benefit, and pancreatic cancer trials have shown that later follow-up can soften an initially dramatic effect. The NAPOLI-1 experience is a cautionary example: the first report showed an overall survival improvement with nanoliposomal irinotecan plus fluorouracil and folinic acid, but longer follow-up attenuated the hazard ratio.
Informative censoring adds another layer of uncertainty. In RASolute 302, 15.1% of patients assigned to chemotherapy never received protocol treatment, compared with 2.8% in the daraxonrasib arm. Reconstructed individual-level survival patterns also suggested more early censoring in the control arm over the first 3 months. If healthier or more treatment-seeking patients were more likely to leave the study after assignment to chemotherapy, the comparison could be biased in favor of daraxonrasib. The exact reason for dropout matters, and granular reporting of those departures will be needed before the survival estimate can be viewed as fixed.
Toxicity was not trivial. Grade 3 or higher treatment-related adverse events occurred in 43.6% of patients receiving daraxonrasib. Rash was common, appearing in 85.5% of patients and reaching grade 3 or higher in 13.7%; stomatitis occurred in 53.1% and reached grade 3 or higher in 12.0%; diarrhea affected 58.1% and reached grade 3 or higher in 5.4%. Even so, only 1.2% discontinued treatment because of side effects. Continuous exposure to a targeted agent creates a different burden than cyclic chemotherapy, and the absence of frequent formal discontinuation for adverse events does not mean the regimen is easy to live with.
Patients discontinued daraxonrasib for several reasons beyond toxicity. Disease progression accounted for most discontinuations, but investigator withdrawal for symptomatic deterioration and patient withdrawal also appeared in the dataset. Those categories are clinically meaningful because they can reflect real-world treatment burden even when they are not coded as adverse-event discontinuations. Resistance also remains biologically inevitable. The progression-free survival curve suggests that nearly all patients progress within 12 months, with no clear plateau, which is consistent with selective pressure driving resistant clones.
Why Timing May Matter as Much as Drug Choice
Daraxonrasib may be most valuable not only because it works, but because it works against a target deeply embedded in pancreatic cancer biology. Active-state RAS inhibition speaks to the core signaling dependency of the disease, and that plausibility explains the magnitude of response. Yet the same biology creates pressure for adaptation, and the timing of exposure may influence how quickly resistance emerges. First-line use could preserve fitness and reduce disease burden earlier, but it could also accelerate resistance before patients have received established chemotherapy backbones. No randomized dataset yet answers that question.
The phase III second-line result has already fueled enthusiasm, and that enthusiasm is understandable in a disease with limited progress. It also creates a communication problem. Patients and families may infer that immediate access is obviously preferable, and that assumption can erode the very clinical equipoise needed to test the drug properly in the first-line setting. The experience with sotorasib in non-small cell lung cancer showed how early excitement, off-label demand, differential dropout, and shifting investigator behavior can complicate confirmatory trials. A similar dynamic could affect daraxonrasib if first-line testing is not designed carefully.
RASolute 303 Needs a Comparator That Reflects Current Care
RASolute 303 is already underway and randomizes patients with first-line metastatic pancreatic ductal adenocarcinoma 1:1:1 to daraxonrasib monotherapy, daraxonrasib plus gemcitabine/nab-paclitaxel followed by daraxonrasib maintenance, or gemcitabine/nab-paclitaxel alone. The coprimary endpoints are progression-free survival and overall survival. The combination arm uses a reduced daraxonrasib dose of 200 mg once daily and comes from phase I-II experience, where grade 3 or higher rash, diarrhea, and stomatitis or mucositis remained clinically challenging despite dose reduction.
The chemotherapy backbone in that arm is also delivered at a lower dose intensity than standard gemcitabine/nab-paclitaxel schedules. That detail is not a footnote; it affects how efficacy will be interpreted. A weaker chemotherapy schedule can make a combination look better than it would against full-intensity contemporary treatment. In a first-line trial, control selection shapes the meaning of the whole experiment.
Crossover and Chemotherapy Choice Will Shape the Interpretation
A chemotherapy-only arm with mandated crossover is the most defensible way to preserve equipoise after the survival signal seen in RASolute 302. Patients randomized to chemotherapy should have a path to receive daraxonrasib later, because the question being asked is timing, not access. Without that safeguard, dropouts to off-label use could distort outcomes and weaken the trial’s credibility.
The control arm also needs to reflect real-world first-line practice. Gemcitabine/nab-paclitaxel is widely used, but it is not the only active standard for fit patients. FOLFIRINOX and NALIRIFOX both have strong evidence in metastatic pancreatic cancer, and guideline bodies do not align perfectly on how to rank them against gemcitabine/nab-paclitaxel. Restricting the comparator to gemcitabine/nab-paclitaxel alone may simplify the protocol, but it narrows the clinical relevance of the result. International variation does not remove the need to match the best available standard where possible.
In the end, daraxonrasib has shifted the conversation in pancreatic cancer from whether KRAS biology can be targeted to how that targeting should be sequenced. The second-line data justify excitement, but they do not settle first-line use. Follow-up remains short, censoring is uneven, resistance is expected, and the current control strategy may not fully mirror contemporary practice. Those are not abstract design issues; they determine whether the next trial will answer the question patients actually need answered.